Cardinal Health Inc. (CAH) delivered strong first-quarter results, exceeding earnings and revenue expectations. The company’s Pharmaceutical and Specialty Solutions segment drove growth, leading to an upward revision of the fiscal year 2025 outlook. This strong performance is fueled by a combination of brand and specialty pharmaceutical sales growth, an early launch of COVID-19 vaccine distribution, and positive generics program performance.
Cardinal Health, a leading distributor of pharmaceuticals and medical products, announced strong first-quarter fiscal year 2025 results, highlighting robust performance in its Pharmaceutical and Specialty Solutions segment and leading to an upward revision of its fiscal year outlook. Revenue decreased by 4% to $52.3 billion, but increased by 15% when excluding the impact of a previously communicated large customer contract expiration. The company also raised its non-GAAP diluted earnings per share guidance for fiscal 2025 to $7.75 to $7.90, demonstrating confidence in its future performance.
Cardinal Health (CAH) is exceeding expectations, demonstrating robust financial performance driven by a strong acute care market, expanding specialty business, and a positive outlook for the future. The company’s recent earnings beat, dividend aristocrat status, and bullish stock chart signal a promising investment opportunity.
Cardinal Health reported strong fourth-quarter earnings, exceeding analysts’ expectations and raising its fiscal year 2025 guidance. The company’s pharmaceutical segment saw significant growth, driven by increased sales from existing customers. Analysts responded positively to the earnings announcement, with some increasing their price targets for Cardinal Health stock.
Cardinal Health (CAH) is set to release its fourth-quarter earnings on August 14th. Analysts anticipate strong earnings growth and revenue, but mixed analyst ratings suggest a range of opinions on the stock’s future performance.
Cardinal Health (CAH) is scheduled to report its fourth-quarter fiscal 2024 results on August 14th. Analysts expect strong growth, driven by rising demand for pharmaceutical products and a focus on specialty solutions. The company’s recent acquisition of Specialty Networks and its new distribution center in South Carolina are also expected to contribute to positive results. However, the Zacks model does not predict a significant earnings beat.
A new honey almond coffee is available, a study on the drug Makena contained an error, and Cardinal Health expects to lose earnings due to losing OptumRx contracts.
Cardinal Health’s pharmaceutical distribution contracts with OptumRx, a subsidiary of UnitedHealth Group, will not be renewed beyond June 2024. Despite this, Cardinal Health reaffirmed its fiscal 2024 adjusted EPS guidance and remains committed to its long-term growth targets. The company expects to partially offset the impact of OptumRx through new customer acquisitions and specialty growth.
